<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03523858</url>
  </required_header>
  <id_info>
    <org_study_id>MN39159</org_study_id>
    <nct_id>NCT03523858</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis</brief_title>
  <acronym>CONSONANCE</acronym>
  <official_title>An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, multicenter, open-label, single-arm effectiveness and safety
      study in participants with progressive multiple sclerosis (PMS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 28, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 29, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants with No Evidence of Progression (NEP)</measure>
    <time_frame>Baseline to Week 192</time_frame>
    <description>NEP is defined as no progression sustained for at least 24 weeks on confirmed disability progression (CDP, as measured by the EDSS), ≥20% increase in timed 25-foot walk test (T25FWT), and ≥20% increase in nine-hole peg test (9HPT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants with NEP Sustained For At Least 24 Weeks and No Active Disease (NEPAD)</measure>
    <time_frame>Baseline to Week 192</time_frame>
    <description>NEPAD is defined as no progression on all of the three components of NEP (CDP as measured by the EDSS), no protocol-defined relapse, no enlarging or new T2 lesion, and no T1 gadolinium (Gd)-enhancing lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Cognitive Function, as Measured by the Symbol Digit Modalities Test (SDMT)</measure>
    <time_frame>Baseline to end of study (Week 192)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Patient-Reported Outcomes (PROs)</measure>
    <time_frame>Baseline to end of study (Week 192)</time_frame>
    <description>PROs collected in this study will be the Multiple Sclerosis Impact Scale (MSIS-29), the Multiple Sclerosis Walking scale (MSWS-12), the ABILHAND Questionnaire, and the Fatigue Scale for Motor and Cognitive function (FSMC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the Expanded Disability Status Scale (EDSS) score over the course of the study</measure>
    <time_frame>Baseline to end of study (Week 192)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of First Confirmed Disability Progression (CDP) Sustained For At Least 24 Weeks</measure>
    <time_frame>Baseline to onset of first CDP (as measured by EDSS) sustained for at least 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of First &gt;=20% Increase in Timed 25-foot Walk Test (T25FWT) Sustained For At Least 24 Weeks</measure>
    <time_frame>Baseline to onset of first &gt;=20% increase in T25FWT sustained for at least 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of First &gt;=20% Increase in 9 Hole Peg Test (9HPT) Sustained For At Least 24 Weeks</measure>
    <time_frame>Baseline to onset of first &gt;=20% increase in 9HPT sustained for at least 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with NEP</measure>
    <time_frame>Week 24 to Week 96, Week 24 to Week 192, and Week 48 to Week 192</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with NEPAD</measure>
    <time_frame>Week 24 to Week 96, Week 24 to Week 192, Week 48 to Week 192</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment or Study Discontinuation</measure>
    <time_frame>Baseline to week 192</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Whole Brain Volume</measure>
    <time_frame>Baseline to end of study (Week 192)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cortical Gray Matter Volume</measure>
    <time_frame>Baseline to end of study (Week 192)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total T2 Lesion Volume</measure>
    <time_frame>Baseline to end of study (Week 192)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Slowly Evolving Lesions (SEL)</measure>
    <time_frame>Baseline to end of study (Week 192)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total T1 Gadolinium (Gd)+ Lesion</measure>
    <time_frame>'Baseline to end of study (Week 192)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of T1 Gd-enhancement in New Focal T2 Lesions, SELs, Persistent Areas of Non-SEL T2 Lesions, and Normal-Appearing Brain Tissue</measure>
    <time_frame>Baseline to end of study (Week 192)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cerebral White Matter Volume</measure>
    <time_frame>Baseline to end of study (Week 192)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gd-enhancing Fluid-Attenuated Inversion-Recovery (FLAIR) Meningeal Lesions</measure>
    <time_frame>Baseline to end of study (Week 192)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spectroscopic MR: Measure of the Relative Signal Amplitude of N-Acetyl Aspartate (NAA), and Choline to Creatine</measure>
    <time_frame>'Baseline to end of study (Week 192)</time_frame>
    <description>Only in centers with 1.5-Tesla MRI capable to perform it</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of Phase Rim Lesions by T2*</measure>
    <time_frame>'Baseline to end of study (Week 192)</time_frame>
    <description>Only in centers with 3-Tesla MRI capable to perform it, where this sequence would replace the spectroscopic MR in the acquisition flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brain Tissue Integrity as Measured by Signal Mass Analysis</measure>
    <time_frame>'Baseline to end of study (Week 192)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Precentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Baseline to end of study (Week 192)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in smartphone-based Floodlight remote patient monitoring (RPM) Test Battery</measure>
    <time_frame>Baseline to Week 48 and baseline to end of study (Week 192)</time_frame>
    <description>Floodlight RPM Test Battery encompasses the following measures:
Information processing speed (IPS) test
Draw a Shape Test
Pinching Test
2-Minute Walking test (2MWT)
U-Turn test (UTT)
Static balance test (SBT)
Continuous sensor-based passive Analysis of mobility and Gait-related motion (CAG)
Daily Mood Questions (DMQ)
Smartphone version of MSIS-29
MS Symptom Tracker (MSST)
During the first 48 weeks of the study, patient will be randomized according to the following two assessment groups to which patients will be randomly allocated in 3:1 ration:
Group 1 will receive a preconfigured and locked-in smartphone and will use the Floodlight RPM solution installed on the smartphone (n=450)
Group 2 will not receive a smartphone and will not use the Floodlight RPM solution (n=150) From Week 48 to 192, all study participants (n=600) will use the Floodlight RPM solution'</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Progressive Multiple Sclerosis (PMS)</condition>
  <arm_group>
    <arm_group_label>Ocrelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ocrelizumab will be administered via intravenous (IV) infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ocrelizumab</intervention_name>
    <description>Ocrelizumab will be administered via intravenous (IV) infusion at an initial dose of two 300-mg infusions separated by 14 days (on Days 1 and 15), and then 600 mg at every subsequent dose every 24 weeks for the remainder of the study treatment period (approximately 192 weeks)</description>
    <arm_group_label>Ocrelizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a length of disease duration since Progressive Multiple Sclerosis (PMS) disease
             symptom onsent &lt;= 10 years if baseline Expanded Disability Status Scale (EDSS) &lt;=5.0
             and &lt;=15 years if baseline EDSS &gt;5.0

          -  Have experience of having used a smartphone and connecting a smartphone to Wi-Fi
             network providers.

          -  For women of childbearing potential: agreement to use an acceptable birth control
             method during the treatment period and for at least 6 months after the last dose of
             study drug.

          -  EDSS (Expanded Disability Status Scale) ≤6.5 at screening

          -  Have a documented evidence of disability progression independent of relapse at any
             point in time over the 2 years prior to the screening visit. In case relapse(s) have
             occurred in the last 2 years, disability progression will have to be considered as
             independent of relapse activity as per treating physician's judgment

        Exclusion Criteria:

          -  Gadolinium (Gd) intolerance

          -  Known presence of other neurological disorders Exclusions Related to General Health

          -  Any concomitant disease that may require chronic treatment of systemic corticosteroids
             or immunosuppressants during the course of the study

          -  History or currently active primary or secondary immunodeficiency

          -  Lack of peripheral venous access

          -  Hypersensitivity to ocrelizumab or to any of its excipients

          -  Significant or uncontrolled somatic disease or any other significant disease that may
             preclude participant from participating in the study.

          -  Active infections must be treated and resolved before possible inclusion in the study.

          -  Participants in a severely immunocompromised state until the condition resolves

          -  Participants with known active malignancies or being actively monitored for recurrence
             of malignancy

          -  Participants who have or have had confirmed progressive multifocal leukoencephalopathy
             (PML)

        Exclusions Related to Medications

          -  All vaccines should be given at least 6 weeks before the first infusion of
             ocrelizumab. Live/live attenuated vaccines should be avoided during treatment and
             safety follow-up period until B cells are peripherally repleted.

          -  Treatment with any investigational agent within 24 weeks of screening (Visit 1) or
             five halflives of the investigational drug (whichever is longer) or treatment with any
             experimental procedures for MS

          -  Previous treatment with B-cell targeted therapies, alemtuzumab, total body
             irradiation, or bone marrow transplantation

          -  Previous treatment with natalizumab, daclizumab or figolimod in the last 8 weeks.

          -  Previous treatment with natalizumab where PML has not been excluded according to
             specific algorithm

          -  Participants previously treated with teriflunomide, unless an accelerated elimination
             procedure is implemented until its completion before screening visit

          -  Previous treatment with azathioprine, cyclophosphamide, mycophenolate mofetil or
             methotrexate in the last 12 weeks.

          -  Previous treatment with mitoxantrone, cyclosporine or cladribine in the last 96 weeks.

          -  Contraindications to or intolerance of oral or intravenous (IV) corticosteroids,
             including methylprednisolone administered IV, according to the country label

          -  Treatment with fampridine/dalfampridine (Fampyra)/Ampyra) or other symptomatic MS
             treatment unless on stable dose for ≥30 days prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: MN39159 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MS Center of California</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale University Multiple Sclerosis Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06473</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago; Neurology/MC 2030</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital; Neurological Clinical Research Institute (NCRI)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Elliot Lewis Center</name>
      <address>
        <city>Wellesley</city>
        <state>Massachusetts</state>
        <zip>02481</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wayne State University School of Medicine</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The MS Center of Northeastern New York</name>
      <address>
        <city>Latham</city>
        <state>New York</state>
        <zip>12110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati; Department of Neurology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurology Clinic PC</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Texas Neurology Consultants</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurology Center of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Multiple Sclerosis Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalo-Universitaire Mustapha Bacha; Neurology Service</name>
      <address>
        <city>Algiers</city>
        <zip>16000</zip>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of Belloua; Neurology Service</name>
      <address>
        <city>Tizi Ouzou</city>
        <zip>15006</zip>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinical Center of the Republic of Srpska; Neurology Clinic</name>
      <address>
        <city>Banja Luka</city>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Mostar; Neurology Clinic</name>
      <address>
        <city>Mostar</city>
        <zip>88000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Center University of Sarajevo; Neurology clinic</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fraser Health Multiple Sclerosis Clinic; Burnaby Hospital Pharmacy</name>
      <address>
        <city>Burnaby</city>
        <state>British Columbia</state>
        <zip>V5G 2X6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre Uni Campus</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Michael'S Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Recherche Sepmus, Inc.</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2J2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chum Campus Notre Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínica Biblica</name>
      <address>
        <city>San José</city>
        <zip>10101</zip>
        <country>Costa Rica</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jihlava; NEU-Neurologicke oddeleni</name>
      <address>
        <city>Jihlava</city>
        <zip>58633</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultní Nemocnice Olomouc; Neurologicka Klinika</name>
      <address>
        <city>Olomouc</city>
        <zip>77521</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Ostrava; Neurologicka Klinika</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze; MS Centrum, Neurologicka klinika</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital, Neurologisk Afd. F, Skleroseklinikken</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet; Neurologisk Klinik Glostrup</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Righospitalet, Dansk Multipel Sclerose Center, Neurologisk Klinik.</name>
      <address>
        <city>København</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sydjysk Skleroseklinik - Sønderborg</name>
      <address>
        <city>Sønderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Hopital Sud; Neurologie</name>
      <address>
        <city>Amiens Cedex1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHIC Cote Basque Bayonne; Neurologie</name>
      <address>
        <city>Bayonne Cedex</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pellegrin; Service de Neurologie - 3ème étage</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU De Caen; Service De Neurologie Dejerine</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital B Roger Salengro; Neurologie C</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone - Hopital d Adultes; Service de Neurologie</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Gui de Chauliac; Neurologie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy; Service de neurologie</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Nord Laennec</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Pasteur; Service de Neurologie</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalo-Universitaire Caremeau; Service Neurologie</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Civil de Strasbourg; Service de Neurologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nucare</name>
      <address>
        <city>Ciudad Guatemala</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem AOK; Neurologiai Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jahn Ferenc Dél-Pesti Kórház</name>
      <address>
        <city>Budapest</city>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>VALEOMED Diagnosztikai Központ; VALEOMED Diagnosztikai Központ</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jósa András Oktatókórház</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pécsi Tudományegyetem, Klinikai Központ Neurológiai Klinika; Klinikai Központ Neurológiai Klinika</name>
      <address>
        <city>Pécs</city>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grupo Medico de Investigacion Clinica Multidisciplinaria</name>
      <address>
        <city>Mexico City</city>
        <state>Mexico CITY (federal District)</state>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinstile S.A de C.V.</name>
      <address>
        <city>Mexico City</city>
        <state>Mexico CITY (federal District)</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General de Mexico</name>
      <address>
        <city>Mexico</city>
        <state>Tlaxcala</state>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unidad de investigacion en salud (UIS); Neurociencias</name>
      <address>
        <city>Ciudad de México</city>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Hassan II</name>
      <address>
        <city>FES</city>
        <zip>30000</zip>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Cheikh Zaid</name>
      <address>
        <city>Rabat</city>
        <zip>10000</zip>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Militaire d'Instruction Mohamed V</name>
      <address>
        <city>Rabat</city>
        <zip>10100</zip>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <zip>4819 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Catharina ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maasstadziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3079 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medisch Centrum</name>
      <address>
        <city>Sittard-Geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Consultorios Médicos PaItilla</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny w Bialymstoku</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie; Oddział kliniczny Neurologii</name>
      <address>
        <city>Kraków</city>
        <zip>31-503</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Neurologii Krzysztof Selmaj</name>
      <address>
        <city>Lodz</city>
        <zip>90-324</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SP Swiecickiego UM Marcinkowskiego; Od. Klin. Neurologii z podod. Udarowym</name>
      <address>
        <city>Poznań</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne &quot;MEDYK&quot;</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wojskowy Instytut Medyczny Centralny Szpital Kliniczny MON</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SPSK nr 1; Klinika Neurologii</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jusupovskaya Hospital</name>
      <address>
        <city>Moscow</city>
        <state>Moskovskaja Oblast</state>
        <zip>117186</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scientific Neurology Center; Neurological department #6</name>
      <address>
        <city>Moscow</city>
        <state>Moskovskaja Oblast</state>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vladimirskiy Regional Scientific Research Inst.</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla; Servicio de Digestivo</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron; Servicio de Neurología</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Arrixaca; Servicio de Neurología</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Fe; Servicio de Neurologia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Abu Dhabi</name>
      <address>
        <city>Abu Dhabi</city>
        <zip>112412</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rashid hospital</name>
      <address>
        <city>Dubai</city>
        <zip>4545</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Bosnia and Herzegovina</country>
    <country>Canada</country>
    <country>Costa Rica</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Morocco</country>
    <country>Netherlands</country>
    <country>Panama</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Arab Emirates</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>May 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2018</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

